Clinical characteristics stratified by type and number of mutations
| Characteristic . | Molecular risk signature . | Number of mutations (any) . | |||||
|---|---|---|---|---|---|---|---|
| No ASXL1, EZH2, IDH1/2 mutation (N = 68) . | ≥1 ASXL1, EZH2, IDH1/2 mutation (N = 27) . | P value . | ≤1 mutation (N = 53) . | 2 mutations (N = 30) . | ≥3 mutations (N = 12) . | P value . | |
| Age (years) | 66 (43-84) | 65 (41-80) | .525 | 65 (43-80) | 69 (56-70) | 64 (41-80) | .114 |
| Sex (female) | 28 (41) | 14 (52) | .369 | 21 (40) | 16 (53) | 5 (42) | .473 |
| Hg (g/dL), mean (range) | 10.8 (7.2-16.9) | 10.5 (8.2-13.7) | .499 | 10.7 (7.4-16.9) | 11.1 (8.6-16.7) | 9.7 (7.2-12.0) | .120 |
| WBC (109/L), mean (range) | 25 (2.7-152) | 26 (2.5-159) | .824 | 25 (3-152) | 21 (3-88) | 33 (24-159) | .518 |
| Plt (109/L), mean (range) | 367 (95-874) | 269 (13-637) | .043 | 363 (95-835) | 351 (103-969) | 206 (165-637) | .027 |
| Plt < 270 × 109/L | 30 (44) | 17 (63) | .115 | 22 (42) | 16 (53) | 9 (75) | .098 |
| PBBL, mean (range) | 1 (0-8) | 1.5 (0-7.0) | .003 | 0.7 (0-4) | 1.2 (0-8) | 1.6 (0-4) | .023 |
| PBBL ≥1% | 15 (22) | 11 (41) | .058 | 17 (32) | 15 (50) | 9 (75) | .017 |
| Baseline spleen size (cm), mean (range) | 18 (0-35) | 19 (3-30) | .732 | 20.0 (11-35) | 17.2 (3-29) | 21.5 (10-30) | .092 |
| Diagnosis | |||||||
| PMF | 33 (49) | 21 (78) | .032 | 26 (49) | 18 (60) | 10 (83) | .031 |
| PPV-MF | 26 (38) | 5 (18) | 23 (43) | 6 (20) | 2 (17) | ||
| PET-MF | 9 (13) | 1 (4) | 4 (8) | 6 (20) | 0 | ||
| Cytogenetics | |||||||
| Diploid | 36 (53) | 18 (67) | .429 | 23 (43) | 22 (73) | 9 (75) | .056 |
| Abnormal | 30 (44) | 8 (30) | 28 (53) | 7 (23) | 3 (25) | ||
| IM | 2 (3) | 1 (3) | 2 (4) | 1 (3) | 0 | ||
| Co-occurring mutations | |||||||
| TET2 (N = 14) | 10 (15) | 4 (15) | .608 | 0 | 10 (33) | 4 (33) | <.001 |
| JAK2 (N = 79) | 59 (87) | 20 (74) | .222 | 47 (88) | 24 (80) | 8 (67) | .157 |
| CALR (N = 9) | 5 (7) | 4 (15) | .622 | 3 (60) | 3 (50) | 3 (75) | .732 |
| Type 1 (N = 7) | |||||||
| Type 2 (N = 2) | |||||||
| Average dose intensity | .150 | .360 | |||||
| ≤10 mg BID | 14 (21) | 6 (22) | 11 (21) | 8 (27) | 1 (8) | ||
| >10 to ≤20 mg BID | 34 (50) | 8 (30) | 26 (49) | 12 (40) | 4 (33) | ||
| >20 mg BID | 20 (29) | 13 (48) | 16 (30) | 10 (33) | 7 (58) | ||
| G3/4 hematologic toxicities | |||||||
| G3/4 anemia/thrombocytopenia | 52 (76) | 18 (67) | .439 | 39 (74) | 23 (77) | 8 (67) | .801 |
| No G3/4 anemia/thrombocytopenia | 16 (24) | 9 (33) | .533 | 13 (25) | 7 (23) | 4 (33) | .830 |
| G3/4 anemia | 27 (40) | 7 (26) | 21 (40) | 9 (30) | 4 (33) | ||
| G3/4 thrombocytopenia | 13 (19) | 5 (19) | 10 (19) | 7 (23) | 1 (8) | ||
| G3/4 anemia and thrombocytopenia | 12 (18) | 6 (22) | 8 (15) | 7 (23) | 3 (25) | ||
| Spleen response (N = 88) | |||||||
| <50% reduction | 12 (20) | 13 (48) | .01 | 10 (21) | 6 (21) | 9 (75) | .001 |
| ≥50% reduction | 49 (80) | 14 (52) | 37 (79) | 23 (79) | 3 (25) | ||
| 0-24% spleen red | 5 (8) | 9 (33) | .009 | 5 (11) | 4 (14) | 5 (42) | .03 |
| 25-100% spleen red | 56 (92) | 18 (67) | 42 (89) | 25 (86) | 7 (58) | ||
| Median IWG SR duration (weeks) (N = 63) | 39.7 (2.8-68.5) | 14.3 (4.6-74.2) | .212 | 41.4 (3.0-68.5) | 22.2 (2.8-74.2) | 6.6 (6.5-6.6) | .080 |
| Median TTD (weeks) | 214 (7-369) | 96 (9-387) | <.001 | 218 (7-369) | 162 (17-387) | 58 (11-137) | .001 |
| Characteristic . | Molecular risk signature . | Number of mutations (any) . | |||||
|---|---|---|---|---|---|---|---|
| No ASXL1, EZH2, IDH1/2 mutation (N = 68) . | ≥1 ASXL1, EZH2, IDH1/2 mutation (N = 27) . | P value . | ≤1 mutation (N = 53) . | 2 mutations (N = 30) . | ≥3 mutations (N = 12) . | P value . | |
| Age (years) | 66 (43-84) | 65 (41-80) | .525 | 65 (43-80) | 69 (56-70) | 64 (41-80) | .114 |
| Sex (female) | 28 (41) | 14 (52) | .369 | 21 (40) | 16 (53) | 5 (42) | .473 |
| Hg (g/dL), mean (range) | 10.8 (7.2-16.9) | 10.5 (8.2-13.7) | .499 | 10.7 (7.4-16.9) | 11.1 (8.6-16.7) | 9.7 (7.2-12.0) | .120 |
| WBC (109/L), mean (range) | 25 (2.7-152) | 26 (2.5-159) | .824 | 25 (3-152) | 21 (3-88) | 33 (24-159) | .518 |
| Plt (109/L), mean (range) | 367 (95-874) | 269 (13-637) | .043 | 363 (95-835) | 351 (103-969) | 206 (165-637) | .027 |
| Plt < 270 × 109/L | 30 (44) | 17 (63) | .115 | 22 (42) | 16 (53) | 9 (75) | .098 |
| PBBL, mean (range) | 1 (0-8) | 1.5 (0-7.0) | .003 | 0.7 (0-4) | 1.2 (0-8) | 1.6 (0-4) | .023 |
| PBBL ≥1% | 15 (22) | 11 (41) | .058 | 17 (32) | 15 (50) | 9 (75) | .017 |
| Baseline spleen size (cm), mean (range) | 18 (0-35) | 19 (3-30) | .732 | 20.0 (11-35) | 17.2 (3-29) | 21.5 (10-30) | .092 |
| Diagnosis | |||||||
| PMF | 33 (49) | 21 (78) | .032 | 26 (49) | 18 (60) | 10 (83) | .031 |
| PPV-MF | 26 (38) | 5 (18) | 23 (43) | 6 (20) | 2 (17) | ||
| PET-MF | 9 (13) | 1 (4) | 4 (8) | 6 (20) | 0 | ||
| Cytogenetics | |||||||
| Diploid | 36 (53) | 18 (67) | .429 | 23 (43) | 22 (73) | 9 (75) | .056 |
| Abnormal | 30 (44) | 8 (30) | 28 (53) | 7 (23) | 3 (25) | ||
| IM | 2 (3) | 1 (3) | 2 (4) | 1 (3) | 0 | ||
| Co-occurring mutations | |||||||
| TET2 (N = 14) | 10 (15) | 4 (15) | .608 | 0 | 10 (33) | 4 (33) | <.001 |
| JAK2 (N = 79) | 59 (87) | 20 (74) | .222 | 47 (88) | 24 (80) | 8 (67) | .157 |
| CALR (N = 9) | 5 (7) | 4 (15) | .622 | 3 (60) | 3 (50) | 3 (75) | .732 |
| Type 1 (N = 7) | |||||||
| Type 2 (N = 2) | |||||||
| Average dose intensity | .150 | .360 | |||||
| ≤10 mg BID | 14 (21) | 6 (22) | 11 (21) | 8 (27) | 1 (8) | ||
| >10 to ≤20 mg BID | 34 (50) | 8 (30) | 26 (49) | 12 (40) | 4 (33) | ||
| >20 mg BID | 20 (29) | 13 (48) | 16 (30) | 10 (33) | 7 (58) | ||
| G3/4 hematologic toxicities | |||||||
| G3/4 anemia/thrombocytopenia | 52 (76) | 18 (67) | .439 | 39 (74) | 23 (77) | 8 (67) | .801 |
| No G3/4 anemia/thrombocytopenia | 16 (24) | 9 (33) | .533 | 13 (25) | 7 (23) | 4 (33) | .830 |
| G3/4 anemia | 27 (40) | 7 (26) | 21 (40) | 9 (30) | 4 (33) | ||
| G3/4 thrombocytopenia | 13 (19) | 5 (19) | 10 (19) | 7 (23) | 1 (8) | ||
| G3/4 anemia and thrombocytopenia | 12 (18) | 6 (22) | 8 (15) | 7 (23) | 3 (25) | ||
| Spleen response (N = 88) | |||||||
| <50% reduction | 12 (20) | 13 (48) | .01 | 10 (21) | 6 (21) | 9 (75) | .001 |
| ≥50% reduction | 49 (80) | 14 (52) | 37 (79) | 23 (79) | 3 (25) | ||
| 0-24% spleen red | 5 (8) | 9 (33) | .009 | 5 (11) | 4 (14) | 5 (42) | .03 |
| 25-100% spleen red | 56 (92) | 18 (67) | 42 (89) | 25 (86) | 7 (58) | ||
| Median IWG SR duration (weeks) (N = 63) | 39.7 (2.8-68.5) | 14.3 (4.6-74.2) | .212 | 41.4 (3.0-68.5) | 22.2 (2.8-74.2) | 6.6 (6.5-6.6) | .080 |
| Median TTD (weeks) | 214 (7-369) | 96 (9-387) | <.001 | 218 (7-369) | 162 (17-387) | 58 (11-137) | .001 |
IM, not measurable.